<DOC>
	<DOC>NCT02784847</DOC>
	<brief_summary>A pilot trial of triheptanoin, a natural compound able to promote anaplerotic mitochondrial metabolism, for the preventative treatment of migraine.</brief_summary>
	<brief_title>A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine</brief_title>
	<detailed_description>To test the ability of a daily 3-month treatment with triheptanoin to prevent migraine attacks in 10 migraine patients. This is an open, non-randomized pilot trial that might justify a placebo-controlled trial, if there are at least 50% of patients with â‰¥50% reduction in attack frequency.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Females aged 1865 years old having an effective contraception or being menopaused Diagnosis of migraine without aura (ICHD3beta 1.1) since at least 2 years 410 migraine days per month during the last 3 months No preventive antimigraine therapy during the last month &gt; 4 tensiontype headache episodes per month Medication overuse headache or other headache types Resistance to &gt;3 previous preventive antimigraine drug treatments Any serious medical or psychiatric condition Ongoing or previous bowel disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>